Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study

Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-world EFFECT Study

10.26226/morressier.59a3e8b6d462b8028d8951f5 ◽

2017 ◽

Cited By ~ 1

Author(s):

Jacob Sloane

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Real World ◽

Dimethyl Fumarate ◽

Effect Study ◽

The Real ◽

Delayed Release ◽

Relapsing Remitting ◽

Prospective real world observational multi-center study in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Campania, Italy

10.26226/morressier.5b719e475aff74008ae4cbcd ◽

2018 ◽

Author(s):

Roberta Lanzillo ◽

Antonio Carotenuto

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Multi Center Study ◽

Relapsing Remitting Multiple Sclerosis ◽

Center Study

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy ◽

10.1007/s40120-019-00174-3 ◽

2019 ◽

Vol 9 (1) ◽

pp. 85-92

Author(s):

Michelle Allan ◽

Lindsay Grant

Keyword(s):

Multiple Sclerosis ◽

Retrospective Analysis ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

Treatment with Delayed-release Dimethyl Fumarate is Associated with Fewer Relapses versus Glatiramer Acetate in Patients with Relapsing Remitting Multiple Sclerosis: Real-world Comparative Effectiveness Analyses from the EFFECT Study

10.26226/morressier.59a3edabd462b8028d89517d ◽

2017 ◽

Author(s):

Andrew Chan

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Real World ◽

Comparative Effectiveness ◽

Dimethyl Fumarate ◽

Effect Study ◽

Delayed Release ◽

Relapsing Remitting ◽

Delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis - findings from a real-world setting in Russian Federation

10.26226/morressier.5b719e475aff74008ae4cbeb ◽

2018 ◽

Author(s):

Maria Davydovskaya

Keyword(s):

Multiple Sclerosis ◽

Russian Federation ◽

Real World ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Real World Setting ◽

Relapsing Remitting ◽

A Real-world Comparison of Infection Rate and Lymphocyte Counts Among Relapsing: Remitting Multiple Sclerosis Patients 50 Years or Older Treated with Subcutaneous Interferon Beta-1a Or Dimethyl Fumarate

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2018.10.089 ◽

2018 ◽

Vol 26 ◽

pp. 259

Author(s):

B. Hayward ◽

S. Cardoso ◽

M. Grosso ◽

S. Ansari ◽

S. Napoli

Keyword(s):

Multiple Sclerosis ◽

Infection Rate ◽

Real World ◽

Interferon Beta ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Relapsing-Remitting Multiple Sclerosis Patients On Dimethyl Fumarate Reported Less Physical And Psychological Disease Impact In The Real World Compared With Patients On Platform Therapies

Value in Health ◽

10.1016/j.jval.2017.08.2652 ◽

2017 ◽

Vol 20 (9) ◽

pp. A887

Author(s):

M Huang ◽

J Pike ◽

W Huang ◽

E Jones

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Dimethyl Fumarate ◽

The Real ◽

Relapsing Remitting ◽

Disease Impact ◽

Multiple Sclerosis Patients ◽

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing–remitting multiple sclerosis in a real-world clinical setting: PROTEC

Multiple Sclerosis Journal - Experimental Translational and Clinical ◽

10.1177/2055217319887191 ◽

2019 ◽

Vol 5 (4) ◽

pp. 205521731988719 ◽

Cited By ~ 2

Author(s):

T Berger ◽

B Brochet ◽

L Brambilla ◽

PS Giacomini ◽

X Montalbán ◽

...

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Clinical Setting ◽

Patient Reported Outcomes ◽

Dimethyl Fumarate ◽

Patient Reported ◽

Relapsing Remitting ◽

Clinical Measures ◽

Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients With Relapsing-Remitting Multiple Sclerosis: Eight-Year Follow-up of an Integrated Analysis of DEFINE, CONFIRM, and ENDORSE

10.26226/morressier.59a3eda8d462b8028d895222 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ralf Gold

Keyword(s):

Multiple Sclerosis ◽

Dimethyl Fumarate ◽

Integrated Analysis ◽

Newly Diagnosed ◽

Delayed Release ◽

Relapsing Remitting ◽

Treatment patterns of relapsing remitting multiple sclerosis (RRMS) in Europe and the United States

10.26226/morressier.59a3edacd462b8028d8958b7 ◽

2017 ◽

Author(s):

Joanna White

Keyword(s):

United States ◽

Multiple Sclerosis ◽

The United States ◽

Treatment Patterns ◽

Relapsing Remitting ◽